Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: SLC25A3

Summary for SLC25A3

Gene information	Gene symbol	SLC25A3
	Ensembl ID	ENSG00000075415
	Entrez ID	5250
	Gene name	solute carrier family 25 member 3
	Synonyms	PHC
	Gene type	protein_coding
	UniProtAcc	Q00325

Top

Dataset with differentially expressed gene: SLC25A3

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.477522	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.380175	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.361904	8.91e-04
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.705804	5.54e-26
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.64739	7.22e-06
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.264002	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.279064	2.64e-08
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	-0.33488	2.35e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.344876	3.41e-02
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.378401	4.82e-18
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Progenitors	-0.651917	1.88e-04
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.494881	1.11e-24
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.281108	8.25e-03
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.304705	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.250525	9.77e-18
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.256939	1.03e-07
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.253399	1.39e-08
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.344604	1.40e-16
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.359855	1.67e-09
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	B cells	-0.946205	2.73e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.370541	2.93e-27
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.303173	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.25833	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.418396	1.99e-21
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.417318	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.347081	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.352379	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.27539	4.51e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.401149	5.01e-11
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.57072	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.42115	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-1.46104	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-1.06979	0.00e+00

Top

Expression of SLC25A3 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to SLC25A3

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating SLC25A3

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
SLC25A3	hsa-miR-139-5p	97.6113	NM_002635
SLC25A3	hsa-miR-629-5p	94.8333	NM_002635
SLC25A3	hsa-miR-3685	92.7899	NM_005888
SLC25A3	hsa-miR-6839-3p	90.2906	NM_002635
SLC25A3	hsa-miR-155-3p	87.5995	NM_005888
SLC25A3	hsa-miR-455-3p	87.3603	NM_002635
SLC25A3	hsa-miR-6760-3p	86.7991	NM_005888
SLC25A3	hsa-miR-101-3p	85.6779	NM_002635
SLC25A3	hsa-miR-144-3p	85.6779	NM_002635
SLC25A3	hsa-miR-421	85.5446	NM_002635
SLC25A3	hsa-miR-6818-5p	84.0539	NM_005888
SLC25A3	hsa-miR-4789-3p	82.7258	NM_005888
SLC25A3	hsa-miR-1277-5p	82.0796	NM_005888

Page: 1

Top

Motifs and transcription factors (TFs) regulating SLC25A3

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
SLC25A3	metacluster_191.2	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).
SLC25A3	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
SLC25A3	transfac_pro__M06292	ZNF766 (directAnnotation).
SLC25A3	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
SLC25A3	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	ETV4; GCM1 (directAnnotation).
SLC25A3	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
SLC25A3	taipale_tf_pairs__GCM1_HOXB13_RTGCGGGTAATAAAN_CAP	GCM1; HOXB13 (directAnnotation).
SLC25A3	metacluster_119.2	CCNT2; GATA1; GATA1; GATA1; GATA1; GATA2; GATA2; GATA2; NCOA1; TAL1; TAL1; TAL1; TAL1; ZNF823 (directAnnotation). GATA1; TAL1; TAL1; TAL1; TAL1 (inferredBy_Orthology).
SLC25A3	taipale_tf_pairs__FOXJ2_ELF1_RMAGAAAACCGAANN_CAP_repr	ELF1; FOXJ2 (directAnnotation).
SLC25A3	jaspar__MA1948.1	ETV5 (directAnnotation).
SLC25A3	transfac_pro__M05858	ZNF625 (directAnnotation).
SLC25A3	taipale_tf_pairs__FOXO1_ELF1_NNGAAAACCGAANM_CAP	ELF1; FOXO1 (directAnnotation).
SLC25A3	transfac_pro__M04887	TCF12 (directAnnotation).
SLC25A3	transfac_pro__M06372	ZNF841 (directAnnotation).
SLC25A3	metacluster_44.7	NKX3-2 (directAnnotation).
SLC25A3	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
SLC25A3	jaspar__MA0748.2	YY2 (directAnnotation).
SLC25A3	transfac_pro__M00652	NRF1 (directAnnotation).
SLC25A3	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
SLC25A3	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
SLC25A3	hdpi__TIMELESS	TIMELESS (directAnnotation).
SLC25A3	metacluster_141.9	TAF1; YY1; YY1 (directAnnotation).
SLC25A3	transfac_pro__M04826	EP300 (directAnnotation).
SLC25A3	transfac_pro__M05888	ZNF467 (inferredBy_Orthology).
SLC25A3	transfac_pro__M06721	ZKSCAN7 (directAnnotation).
SLC25A3	homer__VVRRAACAATGG_Sox7	SOX7 (inferredBy_Orthology).
SLC25A3	transfac_pro__M06019	ZNF98 (directAnnotation).
SLC25A3	transfac_pro__M06959	ZNF425 (directAnnotation).
SLC25A3	taipale_cyt_meth__CREB1_NRTGAYGCGTN_eDBD_meth_repr	CREB1 (directAnnotation).
SLC25A3	taipale_tf_pairs__ELK1_PAX9_RSCGGAACYACGCWYSANTG_CAP	ELK1; PAX9 (directAnnotation).
SLC25A3	transfac_pro__M05421	MYNN (inferredBy_Orthology).
SLC25A3	transfac_pro__M04855	IRF4 (directAnnotation).
SLC25A3	transfac_pro__M06493	ZNF668 (inferredBy_Orthology).
SLC25A3	swissregulon__mm__Mafg	MAFG (inferredBy_Orthology).
SLC25A3	taipale_tf_pairs__HOXA3_EOMES_TAATKAGGTGNKA_CAP_repr	EOMES; HOXA3 (directAnnotation).
SLC25A3	taipale_tf_pairs__ELK1_PAX1_RSCGGAACYACGCWYSANTG_CAP	ELK1; PAX1 (directAnnotation).
SLC25A3	transfac_pro__M06214	ZNF33B (directAnnotation).
SLC25A3	transfac_pro__M06408	ZSCAN30 (directAnnotation).
SLC25A3	hocomoco__NR1H3_HUMAN.H11MO.1.B	NR1H3 (directAnnotation).
SLC25A3	metacluster_88.2	ZNF274 (directAnnotation).
SLC25A3	transfac_pro__M01725	NR2C2 (directAnnotation).
SLC25A3	transfac_public__M00095	CUX1 (directAnnotation).
SLC25A3	transfac_pro__M06504	ZFP62 (directAnnotation).
SLC25A3	transfac_pro__M06806	PEG3 (directAnnotation).
SLC25A3	metacluster_197.2	E2F4; E2F7; E2F7; E2F7; E2F8; E2F8 (directAnnotation).
SLC25A3	transfac_pro__M02913	SP140 (inferredBy_Orthology).
SLC25A3	metacluster_15.3	E2F1; E2F6; E2F8; E2F8; TFDP1 (directAnnotation). E2F3 (inferredBy_Orthology).
SLC25A3	taipale__ELK1_full_NACTTCCGSCGGAARMN_repr	ELK1 (directAnnotation).
SLC25A3	taipale_tf_pairs__ETV2_FOXI1_RNCGGAANNAAACA_CAP_repr	ETV2; FOXI1 (directAnnotation).
SLC25A3	transfac_pro__M06173	ZNF85 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."